Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Caregiver Reports of Lucid Episodes in Alzheimer's Dementia and Lewy Body Dementias.

Journal of geriatric psychiatry and neurology·2026
Same author

Combining post-mortem and neuroimaging measures of brain amyloidosis to accelerate genomic discovery.

Brain : a journal of neurology·2026
Same author

Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio.

JAMA neurology·2026
Same author

Remote, unsupervised assessment of cognitive impairment and decline in Alzheimer's disease using the Cogstate Brief Battery in ADNI-3.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Identification and quantification of Hypocretin-1/Orexin-A 1-14 and 1-16 fragments in immunopurified cerebrospinal fluid using LC-MS: Comparison with radioimmunoassay (RIA) determinations.

Sleep medicine·2026
Same author

Health system patterns of imaging and fluid biomarker testing in the era of anti-amyloid therapies.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Susan Ashrafzadeh-Kian1, Joshua A Bornhorst1, Daniel Figdore1

  • 1Mayo Clinic, Rochester, MN, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

阿尔茨海默病 (AD) 血液生物标志物如GFAP和p-tau217在接受莱卡尼马布治疗的患者中下降. 这些变化表明,在阿尔茨海默病患者中,有可能监测治疗反应.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

科学领域:

  • 神经科学是一个神经科学.
  • 生物标志物研究 生物标志物研究
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 阿尔茨海默病 (AD) 血液生物标志物 (BBM) 显示出对抗粉样蛋白疗法的监测有前途.
  • 在ADBBM中个体级别的变化需要进一步了解治疗监测.

研究的目的:

  • 在接受lecanemab治疗的患者中评估ADBBM的纵向变化.
  • 确定AD BBMs是否可以反映治疗反应和粉样蛋白清除.

主要方法:

  • 从接受lecanemab的患者收集的长度EDTA血样本.
  • 评估的p-tau217,p-tau181,GFAP,NfL,Aβ42,Aβ40,Aβ42/40,以及p-tau217/Aβ42.0的情况.
  • 分析了基于6个月内生物标志物变化的生物标志物差异和患者组的中位数.

主要成果:

  • 3个月后没有显著的生物标志物中位数变化.
  • 在6个月后,Aβ42/40的中位数显著下降 (p=0.0058).
  • GFAP,p-tau217和Aβ42/40显示最频繁的下降 (分别为80%,60%,60%的患者).

结论:

  • 在lecanemab治疗后,GFAP,p-tau217和Aβ42/40经常出现下降.
  • 目前正在进行的收集旨在将AD BBM变化与Amyloid PET相关联.
  • 这些初步发现支持AD BBM在监测lecanemab治疗中的实用性.